Database Query Results : erastin, ,

erastin, erastin: Click to Expand ⟱
Features:
Erastin is often referred to as a "metabolic inhibitor" or a "ferroptosis inducer", rather than a traditional chemotherapy agent.
Erastin is primarily available as a research chemical—it's not an approved therapeutic for clinical use.

Pathways:
-Erastin inhibits system xCT, thereby reducing cystine uptake. This leads to decreased intracellular cysteine, a precursor for GSH. As a consequence, the cell’s glutathione levels drop, compromising its ability to neutralize reactive oxygen species (ROS).
-Glutathione (GSH) Depletion and Increased Oxidative Stress
-Voltage-Dependent Anion Channels (VDACs): Altering VDAC function can affect mitochondrial metabolism, leading to changes in energy production and further enhancing oxidative stress.
Scientific Papers found: Click to Expand⟱
727- Bor,  RSL3,  erastin,    Enhancement of ferroptosis by boric acid and its potential use as chemosensitizer in anticancer chemotherapy
- in-vitro, Liver, HepG2
ROS↑, GSH↓, TBARS↑, Ferroptosis↑, ChemoSen↑,
2204- erastin,    Regulation of ferroptotic cancer cell death by GPX4
- in-vitro, fibroS, HT1080
GSH↓, Ferroptosis↑, ROS↑, GPx↓, GPx4↓, lipid-P↑, eff↓, eff↑,
2455- erastin,    Discovery of the Inhibitor Targeting the SLC7A11/xCT Axis through In Silico and In Vitro Experiments
- in-vitro, Cerv, HeLa
xCT↓, GSH↓, ROS↑, TumCMig↓,
5046- erastin,  SAS,    The structure of erastin-bound xCT–4F2hc complex reveals molecular mechanisms underlying erastin-induced ferroptosis
- Study, Var, NA
xCT↓, ROS↑, TumCG↓, GSH↓, Ferroptosis↑,
5047- erastin,    The ferroptosis inducer erastin irreversibly inhibits system xc− and synergizes with cisplatin to increase cisplatin’s cytotoxicity in cancer cells
- in-vitro, Ovarian, NA
xCT↓, GSH↓, Ferroptosis↑, ChemoSen↑, eff↑,
5048- erastin,    How erastin assassinates cells by ferroptosis revealed
- Review, Var, NA
Ferroptosis↑, xCT↓, lipid-P↑,
4892- Sper,  erastin,    Spermidine inactivates proteasome activity and enhances ferroptosis in prostate cancer
- in-vitro, Pca, PC3 - in-vivo, Pca, NA
Ferroptosis↑, lipid-P↑, Iron↑, eff↑, HO-1↑, NRF2↑, ROS↑, AntiTum↑, eff↓,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 7

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Ferroptosis↑, 6,   GPx↓, 1,   GPx4↓, 1,   GSH↓, 5,   HO-1↑, 1,   Iron↑, 1,   lipid-P↑, 3,   NRF2↑, 1,   ROS↑, 5,   TBARS↑, 1,   xCT↓, 4,  

Cell Death ⓘ

Ferroptosis↑, 6,  

Proliferation, Differentiation & Cell State ⓘ

TumCG↓, 1,  

Migration ⓘ

TumCMig↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 2,   eff↓, 2,   eff↑, 3,  

Functional Outcomes ⓘ

AntiTum↑, 1,  
Total Targets: 18

Pathway results for Effect on Normal Cells:


Total Targets: 0

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:241  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page